Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Jesús G. Berdeja(Tennessee Oncology), Sundar Jagannath(Mount Sinai Hospital), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Syed Rizvi(Merck (Japan)), Marlene J. Carrasco-Alfonso, Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Frank Fan, Jordan M. Schecter(Centro de Investigación del Cáncer), Xiaoling Wu(South China University of Technology), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Alicia J. Allred(Queen's University Belfast), Dong Geng, Yunsi Olyslager(Janssen (Belgium))
Cited by 78
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k